Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ...
Mar 11, 2026 · Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk …
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple …
Dec 9, 2025 · In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated …
Medical Management and Revascularization for Asymptomatic Carotid ...
Nov 21, 2025 · Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis. Whether adding …
Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute ...
Mar 28, 2026 · Whether anticoagulation alone is an adequate treatment for acute, intermediate-risk pulmonary embolism is uncertain. We conducted a multinational, adaptive-design trial with blinded …
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
Feb 18, 2026 · Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. …
Evolocumab in Patients without a Previous Myocardial Infarction or ...
Nov 8, 2025 · The Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke (VESALIUS-CV) trial was a dedicated cardiovascular-outcomes trial that tested …
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
Mar 11, 2026 · Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by …
First-Line Zongertinib in Advanced - The New England Journal of …
Apr 15, 2026 · Until recently, no first-line targeted treatment options were available for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). …
The New England Journal of Medicine | Research & Review Articles on ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Clinical Practice Topics | The New England Journal of Medicine
Recognizing Historical Injustices in Medicine and the Journal Tobacco Use Reduction Additional Topics A Accountable Care Organizations Acute Coronary Syndromes Acute Kidney Injury Addiction